The open-access journal, PLoS NTDs, celebrated its fifth anniversary. To commemorate this great achievement, the journal compiled editorials and research papers published over the last five years to create a collection, called “The Geopolitics of NTDs.”
The collection focuses on the geographic distribution of NTDs by region to highlight the key differences as well as similarities between the diseases in different areas around the world.
October 11, 2012 | Financial Times
The Financial Times special report “Combating Neglected Diseases” contains in-depth stories and interviews featuring several of Sabin’s key programs, including Sabin Vaccine Development, the Global Network for Neglected Tropical Diseases and the Dengue Vaccine Initiative.
Read the full report here.
The suffering caused by hookworm is not well known in the developed world but in many countries it is all too prevalent. More than 700 million people are infected with hookworm. The largest number of cases occur in impoverished areas of Sub-Saharan Africa, Southeast Asia, China and Latin America. Globally, approximately 3.2 billion people are at risk for hookworm infection.
Hookworm is an intestinal parasite most commonly found in tropical and sub-tropical climates of Africa, Asia and Latin America. Hookworm, one of three members of a family of parasites known as the soil-transmitted helminths (STHs), are half-inch long worms that attach themselves to the intestinal wall and feed on human blood. Left untreated, hookworm causes severe intestinal blood loss leading to iron-deficiency anemia and protein malnutrition, particularly in pregnant women and children.
The development of a successful vaccine is a significant undertaking that takes years to achieve. The Sabin Vaccine Institute Product Development Partnership (PDP) is internationally recognized for its development of safe, effective vaccines against tropical infections including human hookworm, schistosomiasis, Chagas disease, leishmaniasis and SARS. Sabin PDP esteemed partners include:
With over a decade of experience, Sabin PDP has produced a well-rounded model that serves as a blueprint for the development of safe and effective vaccines against vaccine preventable and neglected tropical diseases. Existing capabilities include:
Product Development: Established the infrastructure to engage in antigen discovery, rapid development of scalable manufacturing processes (process development), quality control, preclinical and clinical immunology and stability testing.
Most people have never heard of diseases like elephantiasis, river blindness, snail fever, trachoma, roundworm, whipworm, or hookworm. But one in six people globally, including more than half a billion children, have these organisms living and breeding inside their bodies.
Yet the solution to these diseases is relatively simple: For only 50 cents, we can provide one person with treatment and protection against all seven NTDs for up to one year.